Daiichi Sankyo & AstraZeneca’s sBLA for Enhertu followed by THP accepted in US for patients with high-risk HER2 positive early-stage breast cancer prior to surgery: Tokyo Friday ...
Myc dysregulation in activated macrophages impairs antioxidant defenses, locking them in a vicious cycle that amplifies type I interferon signaling, driving hyperinflammation and immunosuppression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback